BIOCON LTD. - 532523 - Company Statement
Company Statement07-10-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release06-10-2023
BIOCON LTD. - 532523 - Closure of Trading Window
Closure of trading window from October 1, 2023 until 48 hours after declaration of the financial results of the Company for the quarter and half-yearly ended September 30, 2023.29-09-2023
BIOCON LTD. - 532523 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kiran Mazumdar Shaw & Others25-09-2023
BIOCON LTD. - 532523 - Announcement Under Regulation 30 (LODR)- Investor Meet- Intimation
Intimation of Schedule of Meeting with Analyst/Institutional Investor22-09-2023
BIOCON LTD. - 532523 - Intimation Under Reg 30
Disclosure under Regulation 30 regarding imposition of penalty.22-09-2023
BIOCON LTD. - 532523 - Investor Meeting
Meeting conducted with Institutional Investors/Research Analysts22-09-2023
Peter Bains is Biocon's new group CEO
Biopharmaceuticals major Biocon names Peter Bains Group CEO19-09-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release titled ''Biocon Board Appoints Peter Bains as Group CEO''18-09-2023